Leica Biosystems Launches Independently Qualified Menu of IHC Antibodies for Hematopathology

12 Nov 2013
Share
Leica Biosystems announces the launch of the fourth Novocastra™ HD menu, focused on hematopathology. Previously launched were the Novocastra HD menus for breast, head & neck and dermatopathology.

The new Novocastra HD menu for hematopathology is now available for sale in the USA, Canada and the EU. Availability in other regions will follow. The hematopathology menu includes 50 new products.
In response to customer feedback, Novocastra HD products now feature user-friendly, convenient formats and volumes, ideally suited to laboratory workflow needs. In addition, Leica Biosystems partnered with leading external Quality Assurance (QA) body, NordiQC, to independently* assess each antibody to ensure they perform to the high standards necessary for clinical IHC. This demonstrates Leica Biosystems’ commitment to excellence in user convenience and quality.

As a leading provider of reagents and instruments for IHC, Leica Biosystems’ goal is to supply superior products that customers can depend on to deliver accurate and reproducible results. When used together with the BOND immunostainer, Novocastra HD offers an advanced staining solution that delivers a new industry standard in staining quality.


*Independent evaluation by NordiQC according to the manufacturers‘ instructions for use, commissioned and funded by Leica Biosystems

Image caption: Human follicular lymphoma stained with Novocastra HD Bcl-2 antibody, clone bcl2/100/D5

Request Info


Company website

Leica Biosystems
profile photo

Sonia Nicholas
Clinical Diagnostics Editor